Prof Rodney Ho presented at IAS 2023 in Brisbane

Sept 12, 2023

Prof Ho presented TLC-ART work at IAS in Brisbane last July. TLC-ART has proposed the transformation of the short-acting HIV treatment, TLD (Tenofovir, Lamivudine, Dolutegravir), into a long-acting, single-injection formula that is stable in vivo and in nonhuman primates. This new formulation addresses “pill fatigue” and offers consistent treatment effects lasting over four weeks. This advancement paves the way for more efficient HIV treatments and a potential new standard in patient care.

IAS 2023 proceedings.

Contact: tlcart@uw.edu

New study in JIAS highlights U.S. patient preferences for long-acting HIV treatment

The study explores preferences for long-acting antiretroviral therapy (LA-ART) regimens among people with HIV (PWH) in the United States.

Summary of 2022-2023 TLC-ART Conferences and Presentations to date

2023 LEAP CROI 2023 Workshop in Seattle – Rodney Ho and Simone Perazzolo as plenary talks.

LEAP Logo

February 20, Seattle

The Long-Acting Extended Release Antiretroviral Research Resource Program (LEAP) virtually convened clinicians, investigators, developers, community advocacy groups, not-for-profit institutions, and regulatory authorities. Attendees shared their diverse perspectives and discussed updates, challenges, and future directions in the development of LA formulations. The meeting served as a forum to collectively advance the long-acting field. The Workshop consisted of two Plenary Sessions and four Focus Groups. Below, you’ll find links to video recordings and text summaries of the Plenary and Focus Group presentations.

TLC-ART Lab Update on HIV Therapies at LEAP Conference

Seattle, WA (Feb 12, 2022)–Earlier this month, Dr. Rodney Ho presented updates on the TLC-ART program’s Unitaid funded Global Long-Acting Drug Development (GLAD) Project at the LEAP (Lon-Acting/Extended Release Antiretroviral Research Resource Program) annual meeting.

As part of this meeting, Dr. Ho lectured on the progress of the GLAD project in transforming the current best-of-class oral daily 3-drug pill (Tenofovir, Lamivudine, and Dolutegravir) into a long-acting injectable therapy that can improve patient adherence and provide a higher quality of life for People Living with HIV (PLHIV) globally.

TLC-ART and MPP sign a licence agreement for a long-acting injectable candidate for HIV

TLC-ART program signs a license agreement with MPP to develop long-acting HIV therapeutics.

FDA Approves TLC Alumnus John Hoekman’s Migraine-Treating Nasal Spray

FDA Approves TLC Alumnus Dr. Hoekman’s Migraine Therapy.

TLC-ART Director Dr. Rodney JY Ho Named to National Academy of Inventors

TLC-ART is honored to announce that Director and UWSOP Professor of Pharmaceutics Rodney JY Ho has been elected to the rank of NAI Fellow by the 2020 National Academy of Inventors Fellows Selection Committee and Board of Directors.

“Dr. Ho has demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and the welfare of society,” said NAI President Paul R. Sanberg. “Our sincere congratulations on this well-deserved recognition of his accomplishments, and it is an honor to welcome him as a Fellow. I look forward to working with Dr. Ho in support of NAI’s mission to promote the importance of innovation and celebration of academic invention.”

Dr. Ho Talks Pfizer and COVID-19 Vaccine Distribution with KOMO News 4

Dr. Rodney Ho, Executive Director of WE-REACH, discussed the Pfizer COVID-19 vaccine and the challenges of distributing a treatment that requires -80 degree Celsius freezer storage with KOMO News last Friday. While “it is logistically challenging,” Dr. Ho believes that “we have prepared the best as we can.”

For the full story, follow the link to KOMO News 4.

Drug Topics Covers HIV, COVID-19, and the Role of Pharmacists with Dr. Ho

Drug Topics, a major publication for pharmacists with over 150,000 readers, recently spoke with Dr. Ho about the crucial role of pharmacists in treating the dual crises of COVID-19 and HIV. With the rise of telehealth and the need to understand drug-drug interactions, pharmacists have never been more important for the practice of medicine.

For the full article, follow the link.

KUOW Questions Dr. Ho on FDA Regulations and COVID-19 Testing

Ann Dornfeld, a reporter at KUOW (a local affiliate of NPR), featured Dr. Ho in an article titled “False advertising: This Seattle doctor set up a dubious Covid testing site in a vacant hotel.” In the article, Dr. Ho discusses the issues with FDA oversight of new COVID-19 tests and the problem of false claims test manufacturers can make during the pandemic. For the whole story, follow the link.